Oxygen therapy can be delivered using low-flow, intermediate-flow (air entrainment mask), or high-flow devices. Low/intermediate-flow oxygen devices have several drawbacks that cause critically ill patients discomfort and translate into suboptimal clinical results. These include limitation of the FiO2 (due to the high inspiratory flow often observed in patients with respiratory failure), and insufficient humidification and warming of the inspired gas. High-flow nasal cannula oxygenation (HFNCO) delivers oxygen flow rates of up to 60 L/min and over the last decade its effect on clinical outcomes has widely been evaluated, such as in the improvement of respiratory distress, the need for intubation, and mortality. Mechanisms of action of HFNCO are complex and not limited to the increased oxygen flow rate. The main aim of this review is to guide clinicians towards evidence-based clinical practice guidelines. It summarizes current knowledge about HFNCO use in ICU patients and the potential areas of uncertainties. For instance, it has been recently suggested that HFNCO could improve the outcome of patients with hypoxemic acute respiratory failure. In other settings, research is ongoing and additional evidence is needed. For instance, if intubation is required, studies suggest that HFNCO may help to improve preoxygenation and can be used after extubation. Likewise, HFNCO might be used in obese patients, or to prevent respiratory deterioration in hypoxemic patients requiring bronchoscopy, or for the delivery of aerosol therapy. However, areas for which conclusive data exist are limited and interventions using standardized HFNCO protocols, comparators, and relevant clinical outcomes are warranted.

Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review / Papazian, Laurent; Corley, Amanda; Hess, Dean; Fraser, John F.; Frat, Jean Pierre; Guitton, Christophe; Jaber, Samir; Maggiore, Salvatore M.; Nava, Stefano; Rello, Jordi; Ricard, Jean Damien; Stephan, François; Trisolini, Rocco; Azoulay, Elie. - In: INTENSIVE CARE MEDICINE. - ISSN 0342-4642. - STAMPA. - 42:9(2016), pp. 1336-1349. [10.1007/s00134-016-4277-8]

Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review

NAVA, STEFANO;TRISOLINI, ROCCO;
2016

Abstract

Oxygen therapy can be delivered using low-flow, intermediate-flow (air entrainment mask), or high-flow devices. Low/intermediate-flow oxygen devices have several drawbacks that cause critically ill patients discomfort and translate into suboptimal clinical results. These include limitation of the FiO2 (due to the high inspiratory flow often observed in patients with respiratory failure), and insufficient humidification and warming of the inspired gas. High-flow nasal cannula oxygenation (HFNCO) delivers oxygen flow rates of up to 60 L/min and over the last decade its effect on clinical outcomes has widely been evaluated, such as in the improvement of respiratory distress, the need for intubation, and mortality. Mechanisms of action of HFNCO are complex and not limited to the increased oxygen flow rate. The main aim of this review is to guide clinicians towards evidence-based clinical practice guidelines. It summarizes current knowledge about HFNCO use in ICU patients and the potential areas of uncertainties. For instance, it has been recently suggested that HFNCO could improve the outcome of patients with hypoxemic acute respiratory failure. In other settings, research is ongoing and additional evidence is needed. For instance, if intubation is required, studies suggest that HFNCO may help to improve preoxygenation and can be used after extubation. Likewise, HFNCO might be used in obese patients, or to prevent respiratory deterioration in hypoxemic patients requiring bronchoscopy, or for the delivery of aerosol therapy. However, areas for which conclusive data exist are limited and interventions using standardized HFNCO protocols, comparators, and relevant clinical outcomes are warranted.
2016
Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review / Papazian, Laurent; Corley, Amanda; Hess, Dean; Fraser, John F.; Frat, Jean Pierre; Guitton, Christophe; Jaber, Samir; Maggiore, Salvatore M.; Nava, Stefano; Rello, Jordi; Ricard, Jean Damien; Stephan, François; Trisolini, Rocco; Azoulay, Elie. - In: INTENSIVE CARE MEDICINE. - ISSN 0342-4642. - STAMPA. - 42:9(2016), pp. 1336-1349. [10.1007/s00134-016-4277-8]
Papazian, Laurent; Corley, Amanda; Hess, Dean; Fraser, John F.; Frat, Jean Pierre; Guitton, Christophe; Jaber, Samir; Maggiore, Salvatore M.; Nava, Stefano; Rello, Jordi; Ricard, Jean Damien; Stephan, François; Trisolini, Rocco; Azoulay, Elie
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/585476
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 65
  • Scopus 241
  • ???jsp.display-item.citation.isi??? 193
social impact